DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Virtual Event

2020 年 11 月 02 日 1:00 下午 - 2020 年 11 月 04 日 4:25 下午

(Central Europe Standard Time)

4051 Basel, Switzerland

Pharmacovigilance Strategies Workshop

Session 6: Signal Management: 2 Years into Eudravigilance

Session Chair(s)

Anja  Van Haren, MSc

Anja Van Haren, MSc

Eudravigilance coordinator

Medicines Evaluation Board (MEB), Netherlands

This session will explore the latest developments in signal detection activities in the EU and how the tools provided by the EMA and other data sources are used to support drug safety monitoring. This session will provide an opportunity to review experience with EudraVigilance from several perspectives more than two years since the launch of the pilot and will discuss the next steps to be taken. Additionally, this session will provide guidance on signal and causality assessment to improve the preparation of cumulative reviews within signal procedures. The Panel Discussion will allow participants to directly interact with individuals working on current issues and future development.

Speaker(s)

Natalie  Bandoo

Cumulative Reviews in Signal Assessment

Natalie Bandoo

MHRA, United Kingdom

Senior Scientific Assessor

Andreas  Iwanowitsch

Managing eRMR Assessment for Generics: Expert Recommendations

Andreas Iwanowitsch

STADA Arzneimittel AG , Germany

Director Medical Affairs / Corporate PV, EU QPPV

Catrinel  Popescu, DVM

Signaling Challenges for Innovators: Portal Access and Reporting

Catrinel Popescu, DVM

Biogen, United Kingdom

Head, Safety Surveillance and Aggregate Reports

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。